Scarica l'app Stockscreener
26.22
3.68%
0.93
Dopo l'orario di chiusura:
26.74
0.52
+1.98%
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline? - Kalkine Media
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - MarketBeat
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan
Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com
TYRA's dabogratinib trial in 2026 could validat... - Pluang
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha
HC Wainwright Brokers Lower Earnings Estimates for TYRA - MarketBeat
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday - MarketBeat
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat - GuruFocus
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings - marketbeat.com
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Tyra Biosciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary - TradingView
Tyra Biosciences Q2 net loss widens on higher R&D expenses - TradingView
Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028 - TradingView
TYRA: Phase 2 trials progress, strong cash runway, and higher R&D drive increased net loss - TradingView
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA - MarketBeat
Discipline and Rules-Based Execution in TYRA Response - Stock Traders Daily
Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP - MarketBeat
Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
BlackRock (TYRA holder) reports 2.98M TYRA Biosciences shares, a 5% passive stake - Stock Titan
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial - tipranks.com
Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors - tipranks.com
Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP - MarketBeat
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Commodore Capital LP Lowers Stake in Tyra Biosciences, Inc. $TYRA - marketbeat.com
TYRA|Tyra Biosciences Inc|Price:31.802|Chg%:+1.172 - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TYRA|Tyra Biosciences Inc|Price:26.510|Chg%:-0.450 - TradingKey
TradingKey - TradingKey
Tyra Biosciences, Inc. Revenue Breakdown – NASDAQ:TYRA - TradingView
Affinity Asset Advisors LLC Makes New $9.86 Million Investment in Tyra Biosciences, Inc. $TYRA - MarketBeat
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC - Traders Union
Tyra Biosciences (TYRA) Q4 2025 earnings summary - Quartr
Tyra Biosciences (TYRA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Tyra Biosciences (TYRA) Proxy filing Summary - Quartr
Tyra Biosciences pursues new treatment strategies for urologic cancers - Traders Union
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Jennison Associates LLC Buys Shares of 632,432 Tyra Biosciences, Inc. $TYRA - MarketBeat
Tyra Biosciences (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Investment; Stock Dips SlightlyProfit Guidance Range - dars.gov.et
Tyra Biosciences (TYRA) Slides 3.35% as Support Near $29.50 HoldsBPI Bull Confirmed - dars.gov.et
Tyra Biosciences (NASDAQ:TYRA) Shares Up 5%Here's Why - MarketBeat
Tyra Biosciences (TYRA) Holds Steady Near Resistance After Marginal DeclineCharm Flow - po-news-eg.net
Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Drives Positive SentimentDividend Growth Analysis - dars.gov.et
Non Muscle Invasive Bladder Cancer Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
William Blair updates conviction list: Oracle in, Meta out and more - Seeking Alpha
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):